Search Results

Now showing 1 - 2 of 2

Some of the metrics are blocked by your
consent settings
Granulomatous liver disease in a referral center in Mexico city
(Elsevier BV, 2025-07)
Ruiz-Manríquez, Jesús
;
Feria-Agudelo, Sandra M.
;
Olivas-Martinez, Antonio
;
Martínez-Sánchez, Froylan D.
;
Azamar-Llamas, Daniel
Introduction and Objectives: Up to 15 % of liver biopsies may reveal granulomas. The underlying causes vary geographically, with marked differences between high- and low-middle-income countries. No studies have examined the etiology of granulomatous liver disease (GLD) in Mexico. This study aims to describe the etiologic profile and clinical outcomes of patients diagnosed with GLD at a tertiary care center in Mexico. Materials and Methods: Retrospective cohort study of patients diagnosed with GLD by liver biopsy between 2001 and 2017. Results: We identified 133 patients with GLD. The most common causes were infectious diseases (36.1 %, n = 48; including 22 mycobacterial infections), foreign body reactions (21.1 %, n = 28), and autoimmune disorders (15.0 %, n = 20). The overall 6-month survival probability was 90.9 % (95 % confidence interval [CI], 86–95 %), declining to 87.5 % (95 % CI, 82–93 %) at 12 months. Patients with autoimmune etiologies had the best prognosis (100 % survival at 6 and 12 months). In contrast, patients with neoplastic GLD had the poorest outcomes, with survival probabilities of 72.7 % (95 % CI, 50.6–100 %) at 6 months and 63.6 % (95 % CI, 40.7–99.5 %) at 12 months. Patients with idiopathic GLD had a favorable short-term prognosis, with a 12-month survival probability of 92 %. Conclusions: In this cohort, infectious diseases were the most common cause of GLD. Prognosis varied by etiology, with idiopathic cases showing favorable short-term outcomes and neoplastic cases exhibiting poor survival rates. ©The authors ©Annals of Hepatology ©Elsevier.
Some of the metrics are blocked by your
consent settings
Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID
(MDPI, 2025)
Olivares-Martínez, Elizabeth
;
Hernández-Ramírez, Diego Francisco
;
Núñez-Álvarez, Carlos Alberto
;
Meza-Sánchez, David Eduardo
;
Chapa, Mónica
The intramuscular administration of polymerized type I collagen (PTIC) for adult symptomatic COVID-19 outpatients downregulated hyperinflammation and improved symptoms. We inferred that LAIR1 is a potential receptor for PTIC. Thus, a binding assay and surface plasmon resonance binding assay were performed to estimate the affinity of the interaction between LAIR1 and PTIC. M1 macrophages derived from THP-1 cells were cultured with 2–10% PTIC for 24 h. Lysates from PTIC-treated THP-1 cells, macrophage-like cells (MLCs), M1, M1 + IFN-γ, and M1 + LPS were analyzed by Western blot for NF-κB (p65), p38, STAT1, and pSTAT1 (tyrosine701). Serum cytokine levels and monocyte LAIR1 expressions (Mo1 and Mo2) were analyzed by luminometry and flow cytometry in symptomatic COVID-19 outpatients on PTIC treatment. PTIC-bound LAIR1 had a similar affinity to collagen in M1 macrophages. It downregulated pSTAT1 in IFN-γ-induced M1. COVID-19 patients under PTIC treatment showed a significant decrease in Mo1 percentages and cytokines (IP-10/MIF/eotaxin/IL-8/IL-1RA/M-CSF) associated with STAT1 and an increase in the Mo2 subset. The inflammatory mediators and Mo1 downregulation were related to better oxygen saturation and decreased dyspnea, chest pain, cough, and chronic fatigue syndrome in the acute and long-term phase of infection. PTIC is an agonist of LAIR1 and downregulates STAT-1 phosphorylation. PTIC could be relevant for treating STAT1-mediated inflammatory diseases, including COVID-19 and long COVID. ©The authors ©MDPI.
1

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results